XML 27 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, PPE, Licensing and Research (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2014
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Research and Product Development            
Product development and research costs   $ 1,675,494 $ 2,063,324 $ 2,890,345 $ 3,377,754  
Investments Available for Sale            
Fair value of investments   34,914,331   34,914,331   $ 40,759,703
Gross unrealized losses   28,975   28,975    
Realized losses   473,871   504,994    
Research and Development            
Research and Development Expense   $ 1,675,494 $ 2,063,324 $ 2,890,345 $ 3,377,754  
Baxter Healthcare Organization            
Revenue Recognition            
Initial Payment Received $ 20,000,000